Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
- PMID: 26015868
- PMCID: PMC4443545
- DOI: 10.1186/s40364-015-0033-4
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
Abstract
Background: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations. Cancers without BRCA1 or BRCA2 loss but with accumulation of similar genomic scars also show increased sensitivity to platinum-based chemotherapy. Therefore, reliable biomarkers to identify DNA repair-deficient cancers prior to treatment may be useful for directing patients to platinum chemotherapy and possibly PARP inhibitors. Recently, three SNP array-based signatures of chromosomal instability were published that each quantitate a distinct type of genomic scar considered likely to be caused by improper DNA repair. They measure telomeric allelic imbalance (named NtAI), large scale transition (named LST), and loss of heterozygosity (named HRD-LOH), and it is suggested that these signatures may act as biomarkers for the state of DNA repair deficiency in a given cancer.
Results: We explored the pan-cancer distribution of scores of the three signatures utilizing a panel of 5371 tumors representing 15 cancer types from The Cancer Genome Atlas, and found a good correlation between scores of the three signatures (Spearman's ρ 0.73-0.87). In addition we found that cancer types ordinarily receiving platinum as standard of care have higher median scores of all three signatures. Interestingly, we also found that smaller subpopulations of high-scoring tumors exist in most cancer types, including those for which platinum chemotherapy is not standard therapy.
Conclusions: Within several cancer types that are not ordinarily treated with platinum chemotherapy, we identified tumors with high levels of the three genomic biomarkers. These tumors represent identifiable subtypes of patients which may be strong candidates for clinical trials with PARP inhibitors or platinum-based chemotherapeutic regimens.
Keywords: Cancer; Genomic scars; Homologous recombination deficiency.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4443545/bin/40364_2015_33_Fig1_HTML.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4443545/bin/40364_2015_33_Fig2_HTML.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4443545/bin/40364_2015_33_Fig3_HTML.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4443545/bin/40364_2015_33_Fig4_HTML.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4443545/bin/40364_2015_33_Fig5_HTML.gif)
Similar articles
-
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x. Breast Cancer Res. 2014. PMID: 25475740 Free PMC article.
-
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670. Breast Cancer Res. 2014. PMID: 25093514 Free PMC article. Review.
-
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
-
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.J Mol Med (Berl). 2018 Jun;96(6):527-536. doi: 10.1007/s00109-018-1643-8. Epub 2018 May 3. J Mol Med (Berl). 2018. PMID: 29725737
-
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.Life Sci. 2020 Nov 15;261:118434. doi: 10.1016/j.lfs.2020.118434. Epub 2020 Sep 14. Life Sci. 2020. PMID: 32941897 Review.
Cited by
-
Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma.Sci Rep. 2024 Jul 22;14(1):16834. doi: 10.1038/s41598-024-67516-6. Sci Rep. 2024. PMID: 39039118 Free PMC article.
-
Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells.Epigenetics. 2024 Dec;19(1):2357518. doi: 10.1080/15592294.2024.2357518. Epub 2024 May 26. Epigenetics. 2024. PMID: 38796857 Free PMC article.
-
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.Sci Rep. 2024 May 17;14(1):11278. doi: 10.1038/s41598-024-61640-z. Sci Rep. 2024. PMID: 38760384 Free PMC article.
-
Mutational landscape of inflammatory breast cancer.J Transl Med. 2024 Apr 18;22(1):374. doi: 10.1186/s12967-024-05198-4. J Transl Med. 2024. PMID: 38637846 Free PMC article.
-
The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.NAR Cancer. 2024 Apr 8;6(2):zcae015. doi: 10.1093/narcan/zcae015. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38596432 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous